Lescarden Inc. | Income Statement

Fiscal year is June-May. All values USD Thousands.
2012
2013
2014
2015
2016
Sales/Revenue
418.70
403.10
397.20
253.00
119.70
Cost of Goods Sold (COGS) incl. D&A
223.10
172.80
276.90
156.10
68.70
Gross Income
195.60
230.40
120.30
97.00
50.90
SG&A Expense
377.10
527.70
294.10
291.30
163.40
EBIT
181.50
297.40
173.80
194.40
112.50
Non Operating Income/Expense
-
44.70
-
2.40
0.00
Interest Expense
4.00
4.80
2.40
1.10
0.30
Pretax Income
185.50
257.40
176.20
193.20
112.70
Consolidated Net Income
185.50
257.40
176.20
193.20
112.70
Net Income
185.50
257.40
176.20
193.20
112.70
Net Income After Extraordinaries
185.50
257.40
176.20
193.20
112.70
Net Income Available to Common
185.50
257.40
176.20
193.20
112.70
EPS (Basic)
-
0.01
0.00
0.00
0.00
Basic Shares Outstanding
40,076.80
45,990.90
48,804.20
63,622.30
63,622.30
EPS (Diluted)
0.00
0.01
0.00
0.00
0.00
Diluted Shares Outstanding
40,076.80
45,990.90
48,804.20
63,622.30
63,622.30
EBITDA
181.50
297.40
173.80
194.40
112.50
Non-Operating Interest Income
0.00
-
-
-
-

About Lescarden

View Profile
Address
420 Lexington Avenue
New York New York 10170
United States
Employees -
Website http://www.catrix.com
Updated 07/08/2019
Lescarden, Inc. is a biotechnology company, which engages in the provision of development of natural, biologic therapies for the chronic wound care, dermatology and osteoarthritis markets. It focuses on research and development of biologic materials with focus on wound healing, clinical skin care, osteoarthritis and cancer applications. The company was founded by John Fletcher Prudden in 1960 and is headquartered in New York, NY.